More Than a CDMO

The End-to-End Support of Your Portfolio

lab safety

Pre-Clinical

Partner with us for cell line and strain development, manufacturability assessments, cell banking and toxicology material generation. Let us guide your path to IND/IMPD submission.

doctor reassuring her senior patient

Clinical Phase I, II

Partner with us to develop your initial clinical process for cGMP drug substance and drug product manufacturing.

doctor asking senior patient health questions

Clinical Phase III

Partner with us to optimize, scale and characterize your process to meet anticipated therapeutic demands.

Family bonding time on the couch

Commercialization

Partner with us for process validation and process performance qualification. Leverage our CMC and regulatory services for your BLA/MAA submission and experience our reliability.

Setting New Standards in
Tomorrow’s Medicines

Building exterior
coins icon
0

Billion USD Invested

in recent years

Spotlight

THOUSAND OAKS, CALIF., November 20, 2024 – FUJIFILM Diosynth Biotechnologies today hosted a celebration for the completion of an expansion of its cell therapy manufacturing facility in Thousand Oaks, California.
HILLERØD, DENMARK, November 5, 2024 – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, proudly announces that the first phase of its expansion at the Hillerød site is ready to bring the new production capacity into operation.  
HOLLY SPRINGS, N.C., November 4, 2024, FUJIFILM Diosynth Biotechnologies, a world leading CDMO, today announced that TG Therapeutics, Inc. (NASDAQ: TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS). 
August 20, 2024 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham.